These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

734 related articles for article (PubMed ID: 25087214)

  • 41. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management.
    Frantz R; Huang S; Are A; Motaparthi K
    Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577817
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stevens-Johnson syndrome and toxic epidermal necrolysis: a 20-year single-center experience.
    Lalosevic J; Nikolic M; Gajic-Veljic M; Skiljevic D; Medenica L
    Int J Dermatol; 2015 Aug; 54(8):978-84. PubMed ID: 25385069
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Toxic Epidermal Necrolysis: A Review of Past and Present Therapeutic Approaches.
    Singh N; Phillips M
    Skin Therapy Lett; 2022 Sep; 27(5):7-13. PubMed ID: 36469487
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Analysis of treatments and deceased cases of severe adverse drug reactions--analysis of 46 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis].
    Yamane Y; Aihara M; Tatewaki S; Matsukura S; Kanbara T; Yamakawa Y; Ikezawa Z
    Arerugi; 2009 May; 58(5):537-47. PubMed ID: 19487835
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis.
    Zimmermann S; Sekula P; Venhoff M; Motschall E; Knaus J; Schumacher M; Mockenhaupt M
    JAMA Dermatol; 2017 Jun; 153(6):514-522. PubMed ID: 28329382
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination therapy: Etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Pham CH; Gillenwater TJ; Nagengast E; McCullough MC; Peng DH; Garner WL
    Burns; 2019 Nov; 45(7):1634-1638. PubMed ID: 31466921
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options.
    Worswick S; Cotliar J
    Dermatol Ther; 2011; 24(2):207-18. PubMed ID: 21410610
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Retrospective Cohort Study of the Management and Outcomes of Children Hospitalized with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis.
    Antoon JW; Goldman JL; Shah SS; Lee B
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):244-250.e1. PubMed ID: 29859332
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of toxic epidermal necrolysis (TEN) with low dose intravenous immunoglobulin in child.
    Habib A; Pasha W; Raza N
    J Coll Physicians Surg Pak; 2010 Mar; 20(3):205-7. PubMed ID: 20392387
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding.
    French LE; Trent JT; Kerdel FA
    Int Immunopharmacol; 2006 Apr; 6(4):543-9. PubMed ID: 16504917
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment.
    Schwartz RA; McDonough PH; Lee BW
    J Am Acad Dermatol; 2013 Aug; 69(2):187.e1-16; quiz 203-4. PubMed ID: 23866879
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical features of Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Sato S; Kanbe T; Tamaki Z; Furuichi M; Uejima Y; Suganuma E; Takano T; Kawano Y
    Pediatr Int; 2018 Aug; 60(8):697-702. PubMed ID: 29888432
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children.
    Koh MJ; Tay YK
    Curr Opin Pediatr; 2009 Aug; 21(4):505-10. PubMed ID: 19474732
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN.
    Morales ME; Purdue GF; Verity SM; Arnoldo BD; Blomquist PH
    Am J Ophthalmol; 2010 Oct; 150(4):505-510.e1. PubMed ID: 20619392
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Steven Johnson Syndrome and Toxic Epidermal Necrolysis in a burn unit: A 15-year experience.
    McCullough M; Burg M; Lin E; Peng D; Garner W
    Burns; 2017 Feb; 43(1):200-205. PubMed ID: 27554629
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Effect of Intravenous Immunoglobulin Combined with Corticosteroid on the Progression of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Meta-Analysis.
    Ye LP; Zhang C; Zhu QX
    PLoS One; 2016; 11(11):e0167120. PubMed ID: 27902746
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness, safety and tolerability of cyclosporine versus supportive treatment in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A record-based study.
    Mohanty S; Das A; Ghosh A; Sil A; Gharami RC; Bandyopadhyay D; Das NK
    Indian J Dermatol Venereol Leprol; 2017; 83(3):312-316. PubMed ID: 28366923
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in China.
    Yang SC; Hu S; Zhang SZ; Huang JW; Zhang J; Ji C; Cheng B
    J Immunol Res; 2018; 2018():4320195. PubMed ID: 29607330
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differences between Stevens-Johnson syndrome versus toxic epidermal necrolysis.
    Nowsheen S; Lehman JS; El-Azhary RA
    Int J Dermatol; 2021 Jan; 60(1):53-59. PubMed ID: 33252832
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study.
    Prins C; Vittorio C; Padilla RS; Hunziker T; Itin P; Förster J; Bröcker EB; Saurat JH; French LE
    Dermatology; 2003; 207(1):96-9. PubMed ID: 12835566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.